


2019

medicina

BUENOS AIRES VOL. 79 Supl. IV - 2019

80° Aniversario



MEDICINA

Volumen 79, Supl. IV, págs. 1-338

medicina

BUENOS AIRES, VOL. 79 Supl. IV - 2019

COMITÉ DE REDACCIÓN

Pablo J. Azurmendi
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Damasia Becú Villalobos
Instituto de Biología y Medicina Experimental-CONICET, Buenos Aires, Argentina

José H. Casabé
Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina

Eduardo L. De Vito
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Isabel Narvaiz Kantor
Organización Panamericana de la Salud (OPS/OMS) (ret.) Argentina

Basilio A. Kotsias
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Gustavo Kusminsky
Hospital Universitario Austral, Buenos Aires, Argentina

Isabel A. Lüthy
Instituto de Biología y Medicina Experimental (IBYME), Buenos

Aires, Argentina

Daniel A. Manigot
Hospital San Juan de Dios, Buenos Aires, Argentina

Jorge A. Manni
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Rodolfo S. Martin
Facultad de Ciencias Biomédicas y Hospital Universitario Austral, Buenos Aires, Argentina

Guillermo D. Mazzolini
Instituto de Investigaciones en Medicina Traslacional-CONICET, Hospital Universitario Austral, Buenos Aires, Argentina

Rodolfo C. Puche
Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe, Argentina

Viviana Ritacco
Instituto Nacional de Enfermedades Infecciosas ANLIS-CONICET, Buenos Aires, Argentina

Guillermo B. Semeniuk
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

MIEMBROS EMÉRITOS

Héctor O. Alonso
Instituto Cardiovascular Rosario, Santa Fe, Argentina

Guillermo Jaim Etcheverry
Facultad de Medicina, UBA, Argentina

María Marta de Elizalde de Bracco
IMEX-CONICET-Academia Nacional de Medicina, Buenos Aires,

Argentina

Christiane Dosne Pasqualini
Academia Nacional de Medicina, Buenos Aires, Argentina

La Tapa (Ver pág. 4)
Atardecer en la tarde
Antonella Ricagni

MEDICINA (Buenos Aires) – Revista bimestral – ISSN 0025-7680 (Impresa) – ISSN 1669-9106 (En línea)

REVISTA BIMESTRAL

Registro de la Propiedad Intelectual N° 02683675

Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires)

Propietario de la publicación: **Fundación Revista Medicina**

Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.

MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.

Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.

Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.

Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Basilio A. Kotsias, Eduardo L. De Vito, Isabel Narvaiz Kantor, Guillermo B. Semeniuk

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,

1427 Buenos Aires, Argentina

Tel. 5287-3827 Int. 73919 y 4523-6619

e-mail: revmedbuenosaires@gmail.com – http://www.medicinabuenosaires.com

Vol. 79, Supl. IV, Noviembre 2019

REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIA 2019

**LXIV Reunión Anual de la
Sociedad Argentina de Investigación Clínica (SAIC)**

**LI Reunión Anual de la
Asociación Argentina de Farmacología Experimental (SAFE)**

**XXI Reunión Anual de la
Sociedad Argentina de Biología (SAB)**

**XXXI Reunión Anual de la
Sociedad Argentina de Protozoología (SAP)**

**IX Reunión Anual de la
Asociación Argentina de Nanomedicinas
(NANOMED-ar)**

**VI Reunión Científica Regional de la Asociación Argentina de Ciencia y
Tecnología de Animales de Laboratorio (AACyTAL)**

**con la participación de
The Histochemical Society**

13 - 16 de noviembre de 2019
Hotel 13 de Julio - Mar del Plata

EDITORES RESPONSABLES

**Dra. Mónica Costas
Dra. Gabriela Marino
Dr. Pablo Azurmendi**

ANNUAL MEETING OF BIOSCIENCE SOCIETIES 2019

**LXIV Annual Meeting of
Sociedad Argentina de Investigación Clínica (SAIC)**

**LI Annual Meeting of
Asociación Argentina de Farmacología Experimental (SAFE)**

**XXI Annual Meeting of
Sociedad Argentina de Biología (SAB)**

**XXXI Annual Meeting of
Sociedad Argentina de Protozoología (SAP)**

**IX Annual Meeting of
Asociación Argentina de Nanomedicinas
(NANOMED-ar)**

**VI Regional Scientific Meeting of Asociación Argentina de Ciencia y
Tecnología de Animales de Laboratorio (AACyTAL)**

**with the participation of
The Histochemical Society**

November 13th – 16th, 2019
Hotel 13 de Julio - Mar del Plata

CHIEF EDITORS

**Dra. Mónica Costas
Dra. Gabriela Marino
Dr. Pablo Azurmendi**

Gustavo WILDFEUER (1) | Cecilia GAMBA(1) | Valeria ROCA(2)

BANCO PÚBLICO DE SANGRE DE CORDÓN UMBILICAL- CRH - HOSPITAL GARRAHAN (1); BANCO PÚBLICO DE SANGRE DE CORDÓN - CRH - HTAL GARRAHAN - CONICET (2)

Abstract/Resumen: Research on advanced therapies holds great therapeutic potential. Among them, cell therapy, based on transplantation of live cells, frequently relies on in vitro cultures with or without genetic modifications. Cross-contamination with unrelated cells and/or with microorganisms are among the most frequent risks related to cell culture. According to local and international standards, cellular therapy products characterization, even those intended for pre-clinical research, should include testing for identity, purity, potency, and viability. Short tandem repeats (STR) analysis is recommended for genetic cell line authentication for research but there is no clear consensus on the analysis for products intended for cell therapy. Our goal is to evaluate whether human leukocyte antigen (HLA) typing, by sequence-specific oligonucleotide (SSO) technology, could be used as a quality control to guarantee cell purity, particularly lack of cross-contamination with unrelated cells that will not be revealed by phenotypic characterization or morphological differences. We chose HLA typing because it is a highly polymorphic set of genes and this technology is commonly used in many typing laboratories including ours. Genomic DNA from 4 mesenchymal cell lines (MSC) was obtained and used to perform SSO-PCR for HLA-A; HLA-B and HLA-DRB1 and Luminex analysis according to standard protocols. To test the ability to detect cross-contamination, we performed gDNA mixes between samples (1:1 - 1:100). For the analysis, we compared the number of positive and negative beads in each sample and in the mixes. We set a minimum of 3 different beads as criteria to define contamination. All 4 cell lines showed a unique HLA profile for HLA-A; HLA-B and HLA-DRB1. Also, we were able to detect cross-contamination in all the mixes assayed up to 1:4 by means of at least 3 different beads for each gene. Cell contaminations lower than 20 % were not detected. HLA typing by SSO-PCR technology is effective to determine lack of cross-contamination with unrelated cells and may be a suitable assay for cellular therapy products.

0885 - COMPARISON OF DEPROTEINIZED BOVINE BONE, BIOGLASS AND, SYNTHETIC HYDROXYAPATITE IN THE BONE HEALING OF A CRITICAL SIZED BONE DEFECT. PRELIMINARY STUDY IN RATS.

Gretel Gisella PELLEGRINI(1) | Macarena Ms GONZALES CHAVES(2) | Ricardo ORZUZA(2) | **Susana Noemi ZENI (1)**

UNIVERSIDAD DE BUENOS AIRES – CONICET. INSTITUTO DE INMUNOLOGÍA, GENÉTICA Y METABOLISMO (INIGEM) (1); UNIVERSIDAD DE BUENOS AIRES. FACULTAD DE ODONTOLOGÍA. CÁTEDRA DE BIOQUÍMICA GENERAL Y BUCAL. (2)

Abstract/Resumen: Bone grafts are important for alveolar bone height and volume preservation necessary for dental implant placement. The development of biomaterials for bone grafting with comparable characteristics and biological effects than those renowned internationally is necessary. Deproteinized bovine bone putty (BB), bioglass (BG) and, synthetic hydroxyapatite (SH) are frequently indicated as bone grafting materials due to their osteoconductive properties. We compared the bone healing response of BB, BG and SH (Odontit Implant Systems, Argentina) in a critical sized bone defect. We created a

bone defect of 4 mm diameter in rat tibiae for implantation with each biomaterial (N=30 rats). Samples were collected at 2 and 4 weeks for histological and histomorphometrical analysis of new bone formation (NBF) and remaining particles of each device (RP). Radiographic analysis was done at T=0 and at 2 and 4 weeks. Results: % of NBF (mean \pm SD): 2 weeks: Control group: 6.60 ± 3.71 ; BB group: $23.23 \pm 3.89^*$; BG group: $18.35 \pm 5.23^*$; SH group: $26.27 \pm 9.30^*$; 4 weeks: Control group: 6.69 ± 2.38 ; BB group: $24.37 \pm 3.66^*$; BG group: $17.45 \pm 6.64^*$; SH group: $32.25 \pm 3.80^*$. % of RP: 2 weeks: Control group: 0 ± 0 ; BB group: $5.04 \pm 1.39^*$; BG group: $3.03 \pm 2.31^*$; SH group: $4.46 \pm 2.87^*$; 4 weeks: Control group: 0 ± 0 ; BB group: $4.45 \pm 2.35^*$; BG group: $2.87 \pm 1.14^*$; SH group: $3.78 \pm 1.68^*$ (* $p < 0.05$ versus control group; $p = NS$ between BB, BG and SH groups). Although SH exhibited a trend towards increased NBF we did not find statistical significance among the three biomaterials. Bone healing at the implanted sites, was accompanied by a progressive inflammatory response consistent with the expected histological stages of bone repairing. The 3 biomaterials exhibited an increased in radiopacity at 2 and at 4 weeks vs. control group indicating NBF. All biomaterials were associated with trabecular bone formation. Although further studies need to be done, our results indicate that BB, BG and SH exhibit similar osteoconductive properties.

0919 - LIPOSOME LOADED COLLAGEN BASED BIOMATERIALS WITH ANTIMICROBIAL ACTIVITY

Pablo Edmundo ANTEZANA (1) | Sofia MUNICOY(1) | Martin BELLINO(1) | Claudio PEREZ(2) | Martin DESIMONE(1)

FACULTAD DE FARMACIA Y BIOQUÍMICA UBA (1); FAC. DE CIENCIAS AGRARIAS, UNIVERSIDAD NACIONAL DE MAR DEL PLATA (UNMDP) (2)

Abstract/Resumen: Hydrogels are promising materials in the field of biomedicine due to its biocompatibility and biodegradability. Liposomes (L) have proved to be an effective vehicle as they are not toxic, biodegradable and can encapsulate and release different drugs in a controlled way. Silver nanoparticles (AgNPs) have proved antibacterial activity. In order to overcome the challenge of developing a long-term antimicrobial material, we report a non-conventional biomaterial with prolonged bactericidal effect based on the incorporation of liposomes encapsulating silver nanoparticles in collagen hydrogels. AgNPs were synthesized by a reduction method and then incorporated in liposomes (L-AgNPs) by the lipid film hydration and extrusion technique. Collagen hydrogels were prepared by exposing a collagen solution extracted from rat tails to a saturated atmosphere of ammonia to induce gelation. Antimicrobial collagen-based scaffolds were prepared by adding AgNPs-containing liposomes suspensions to the collagen gels (Col-L-AgNPs). The optical properties of AgNPs were monitored by UV-vis spectroscopy. The morphology of AgNPs and L-AgNPs was studied by TEM and the structure of collagen gels before and after incorporation of L-AgNPs was analyzed by SEM. The antibacterial efficiency of Col-L-AgNPs was then evaluated on Gram-positive (*S. aureus*) and Gram-negative (*P. aeruginosa*) bacteria and cytotoxicity towards mammalian cells was studied. As a result, AgNPs exhibited well dispersed spherical morphology with an effective diameter between 5 and 20 nm. The L-AgNPs showed an effective diameter of approximately 410 nm. Col-L-AgNP showed an important bactericidal activity against both bacteria and did not affect cell viability. Based on these results, Col-L-AgNPs is promising as a new material that conserves a strong bactericidal activity and biocompatible properties for 72 h which is especially attractive for wound dressing as it does not need to be replaced repetitively.